Magnesium Oxide
drugOn this page
Also known as E-530E530Heavy magnesium oxideINS NO.530INS-530Light magnesium oxideMag oxMag-ox 400MagdoseMagnesiaMagnesia oxydataMagnesii oxidumMagnesium (as oxide)Magnesium oxide component of clenpiqMagnesium oxide component of prepopikMagnesium oxide heavyheavylightMagstar
Summary
Magnesium Oxide (CHEMBL1200572) is an approved small molecule (ATC A02AA02); indicated across 6 conditions including iron deficiency anemia and constipation disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: A02AA02 (+2 more)
- Indications: 6 conditions
- Clinical trials: 29
- Chemistry: 40.305 Da · MgO
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200572 |
| Name | Magnesium Oxide |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 14792 |
| ATC | A02AA02, A12CC10, A06AD02 |
| Molecular formula | MgO |
| Molecular weight | 40.305 |
| InChIKey | CPLXHLVBOLITMK-UHFFFAOYSA-N |
SMILES: O=[Mg]
IUPAC name: oxomagnesium
Also known as: E-530, E530, Heavy magnesium oxide, INS NO.530, INS-530, Light magnesium oxide, Mag ox, Mag-ox 400, Magdose, Magnesia, Magnesia oxydata, Magnesii oxidum
Patent coverage: 396 distinct patent families (708 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 596 (84%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| iron deficiency anemia | 4 | MONDO:0001356 | HP:0001891 |
| constipation disorder | 4 | MONDO:0002203 | HP:0002019 |
| prediabetes syndrome | 3 | MONDO:0006920 | EFO:1001121 |
| type 2 diabetes mellitus | 3 | MONDO:0005148 | MONDO:0005148 |
| autosomal recessive inherited pseudoxanthoma elasticum | 2 | MONDO:0009925 | MONDO:0009925 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 29.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 11 |
| PHASE4 | 6 |
| PHASE3 | 5 |
| PHASE2 | 4 |
| PHASE2/PHASE3 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06580366 | PHASE4 | NOT_YET_RECRUITING | Comparing Sennosid A+B and Sodium Picosulfate/Magnesium Oxide/Citric Acid for Bowel Preparation |
| NCT07173855 | PHASE4 | RECRUITING | Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients |
| NCT00427492 | PHASE4 | COMPLETED | Effect of Postoperative Laxative on Bowel Function After Colonic Surgery |
| NCT00994006 | PHASE4 | COMPLETED | The Absorption of Magnesium Oxide Compared to Citrate in Healthy Subjects |
| NCT01631305 | PHASE4 | COMPLETED | Levothyroxine for Children With Euthyroid Sick Syndrome |
| NCT03054805 | PHASE4 | COMPLETED | The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation |
| NCT00561132 | PHASE3 | COMPLETED | Study of Vanadium Supplement in Patients With Impaired Glucose Tolerance |
| NCT02823912 | PHASE2/PHASE3 | UNKNOWN | Capsaicin Effect on Cytokines Profile in Dyslipidemia |
| NCT03313856 | PHASE2/PHASE3 | COMPLETED | Effect of Oral Administration of a Herbarium Mixture (Guazuma Ulmifolia and Tecoma Stans) on Metabolic Profile in Type 2 Diabetic Patients |
| NCT03341117 | PHASE3 | COMPLETED | Acetylsalicylic Acid and Type 2 Diabetes Mellitus |
| NCT03398031 | PHASE3 | UNKNOWN | Effect of Magnesium Supplement in Early Pregnancy After ICSI |
| NCT03840226 | PHASE3 | UNKNOWN | The Impact of Magnesium on Exercise Tolerance, Quality of Life and Clinical Outcomes in Chronic Heart Failure Patients |
| NCT06950138 | PHASE3 | COMPLETED | Efficacy of Triticum Aestivum Over Vascular Function in Mexican Obese Patients |
| NCT01008904 | PHASE2 | COMPLETED | Magnesium Oxide in Treating Hot Flashes in Menopausal Women With Cancer |
| NCT01439945 | PHASE2 | COMPLETED | Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer |
| NCT01525875 | PHASE2 | COMPLETED | Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE) |
| NCT02129231 | PHASE2 | COMPLETED | Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy |
| NCT03475693 | EARLY_PHASE1 | COMPLETED | A Cohort Study Evaluating the Efficacy of PO Magnesium in the Treatment of Acute Traumatic Brain Injury in Adolescents |
| NCT00247715 | Not specified | COMPLETED | Comparison of a Step-Up Versus a Step-Down Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study) |
| NCT00613366 | Not specified | COMPLETED | Misoprostol With Intrauterine Device Insertion |
| NCT01889576 | Not specified | COMPLETED | The Effect of Magnesium on Early Post-transplantation Glucose Metabolism |
| NCT02178150 | Not specified | UNKNOWN | Effect of Magnesium Supplementation on Polycystic Ovary Syndrome |
| NCT02220036 | Not specified | UNKNOWN | Effect of Magnesium Supplementation on Patients With Diabetic Nephropathy |
| NCT02455726 | Not specified | UNKNOWN | Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease |
| NCT02690012 | Not specified | COMPLETED | Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for the Management of Hypomagnesemia From Anti-Cancer Therapies |
| NCT03632590 | Not specified | UNKNOWN | Magnesium and Vascular Stiffness |
| NCT04033250 | Not specified | UNKNOWN | Personalized Colonoscopy Preparation for Patients With Risk Factors for Inadequate Preparation |
| NCT04216836 | Not specified | COMPLETED | One Week of Magnesium Supplementation Lowers IL-6, Perceived Pain and Increases Post Exercise Blood Glucose in Response to Downhill Running |
| NCT04259606 | Not specified | UNKNOWN | Effect of Cassia Cinnamon on Arterial Stiffness Parameters in Patients With Type 2 Diabetes Mellitus |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).